

# Phase 1a clinical trial and approval of IND for phase 1b/2a clinical trial of androgenic alopecia therapeutics using cell-penetrating RNAi gene regulation technology

Olix Pharmaceuticals



OTHERS	Phase 1
Product Type	Small interfering RNA (siRNA)
Indication	Androgenic alopecia (AGA)
Target	Androgen receptor (AR)
MoA(Mechanism of Action)	Suppresses the effects of androgens, which are closely linked to AGA, by reducing the expression of the AR
Competitiveness	<ul style="list-style-type: none"> <li>• For patients suffering from systemic side effects by delivering the drug directly to loss zones</li> <li>• Alleviates inconvenience caused by frequent administration due to long duration of action</li> <li>• Minimizes medical risks for female AGA patients</li> </ul>
Development Stage	Phase 1
Route of Administration	Intradermal injection